Latest Ratios: P/E Ratio 58.8x · EV/EBITDA 55.6x · ROE -132.9%. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $8.9B | $3.8B | — | — |
| Enterprise Value | $8.7B | $3.6B | — | — |
| P/E Ratio → | 58.82 | — | — | — |
| P/S Ratio | 11.05 | 6.46 | — | — |
| P/B Ratio | 24.69 | 10.02 | — | — |
| P/FCF | 27.78 | 22.23 | — | — |
| P/OCF | 51.64 | 22.13 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | 6.12 | — | — |
| EV / EBITDA | 55.55 | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | 21.06 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | 79.8% | 79.8% | 77.0% | 66.3% |
| Operating Margin | -92.9% | -92.9% | -8.2% | -44.6% |
| Net Profit Margin | -89.9% | -89.9% | -3.1% | -36.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | -132.9% | -132.9% | -2.8% | -25.3% |
| ROA | -74.5% | -74.5% | -1.8% | -17.4% |
| ROIC | -268.2% | -268.2% | -14.3% | -47.0% |
| ROCE | -135.5% | -135.5% | -7.4% | -29.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.03 | 0.04 |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.53 | -0.70 | -0.51 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | -1.17 | -6.41 | — |
| Interest Coverage | — | — | — | — |
Net cash position: cash ($208M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 2.34 | 2.88 |
| Quick Ratio | 1.43 | 1.43 | 2.30 | 2.81 |
| Cash Ratio | 1.00 | 1.00 | 1.87 | 2.30 |
| Asset Turnover | — | 0.79 | 0.58 | 0.47 |
| Inventory Turnover | 7.58 | 7.58 | 8.26 | 7.41 |
| Days Sales Outstanding | — | 41.02 | 39.73 | 58.06 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | 1.7% | — | — | — |
| FCF Yield | 3.6% | 4.5% | — | — |
| Buyback Yield | 0.7% | 1.7% | — | — |
| Total Shareholder Yield | 0.7% | 1.7% | — | — |
| Shares Outstanding | — | $82M | $78M | $78M |
Includes 30+ ratios · 3 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HNGE stock.
Hinge Health, Inc.'s current P/E ratio is 58.8x. This places it at the 50th percentile of its historical range.
Hinge Health, Inc.'s current EV/EBITDA is 55.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Hinge Health, Inc.'s return on equity (ROE) is -132.9%. The historical average is -53.7%.
Based on historical data, Hinge Health, Inc. is trading at a P/E of 58.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Hinge Health, Inc. has 79.8% gross margin and -92.9% operating margin.
Key Metrics
Top Statement Risk
Operating margin recently turned positive
Metrics are mathematically derived from official filings.
Premium Multiples Price in Sustained Growth
HNGE trades at a trailing P/E of 62.57 and an EV/EBITDA of 59.18, with forward P/E compressing to 48.99, suggesting the market is capitalizing growth well ahead of current earnings power based on reported figures.
Compared with its own trailing history, the multiple remains elevated, and the compression from trailing to forward P/E implies analysts expect earnings to roughly double over the coming year. Relative to peers, where Teladoc carries a negative P/E and Omnicell trades at 37.01, HNGE is priced as a growth asset rather than a value holding. Investors should monitor whether margin expansion keeps pace, since the multiple leaves limited room for execution slippage.
Gross Margin Strength Masks Operating Gap
Gross margin expanded from 74.2% in 2024Q2 to 87.0% in 2026Q3, while operating margin reached 21.4%, according to reported quarterly figures, indicating improving unit economics but uneven conversion to operating profit.
The gap between gross margin and operating margin reflects a heavy fixed cost base in sales and R&D that has only recently been absorbed by scale. Net margin of 24.4% in 2026Q3 is flattered by non-operating items, as the 2025Q1 net margin of 98.0% against a much smaller operating result demonstrates. Operating margin is the more reliable gauge of earning power, and its sustained move above zero is the key signal to watch.
ROIC Recovery From Near-Zero Baseline
ROIC climbed from negative territory in 2025Q3 to 40.6% in 2026Q3, and ROE rose to 17.8%, based on reported quarterly ratios, suggesting returns are compounding off a depressed base.
The rapid improvement is driven largely by operating margin recovery rather than capital efficiency, since asset turnover of 0.28 remains low for a software-led model. The ROIC figure may be inflated by a thin invested capital base following the accumulated deficit. Investors should treat the trajectory as encouraging but early, pending confirmation over several more quarters.
Current Ratio Tightens as Cash Builds
The current ratio fell from 2.31 in 2025Q1 to 1.04 in 2026Q3 even as cash reached $211.6M, according to reported figures, indicating a thinner short-term buffer driven by growing current liabilities.
The decline appears tied to deferred revenue and working capital dynamics rather than weaker cash generation, which remained strong. A quick ratio of 1.01 still covers current obligations without relying on inventory, which is minimal for this model. Under severe stress, the position would depend on continued collection of receivables and renewal of enterprise contracts.
Minimal Debt Keeps Solvency Risk Low
Debt-to-equity of 0.11 and debt-to-EBITDA of 0.64 in 2026Q3, based on reported figures, indicate a lightly levered balance sheet with limited refinancing exposure.
Interest coverage is not meaningful given operating income only recently turned positive, so debt service capacity is better judged through cash generation than earnings. The absence of meaningful borrowings suggests covenant risk is low. The leverage profile would only become a concern if operating cash flow reversed sharply.
Deferred Revenue Flatters Cash Quality
Operating cash flow of $114.6M against $57.4M of net income in 2026Q3 appears strong, but according to recent SEC filings, stock-based compensation of $19.5M is added back, so part of the cash strength may reflect equity dilution.
The ratio of operating cash flow to net income is supported by large deferred revenue balances, which mean cash is collected ahead of service delivery and can reverse as contract timing shifts. Treating stock-based compensation as a real cost would lower the adjusted free cash flow margin materially below the reported 47.9%. Investors may wish to monitor deferred revenue growth against recognized revenue to judge whether cash conversion is durable.